Harbin Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 4/6
Harbin Pharmaceutical Group has a total shareholder equity of CN¥5.9B and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 30.2%. Its total assets and total liabilities are CN¥14.3B and CN¥8.3B respectively. Harbin Pharmaceutical Group's EBIT is CN¥816.0M making its interest coverage ratio 146.3. It has cash and short-term investments of CN¥3.1B.
Key information
30.2%
Debt to equity ratio
CN¥1.80b
Debt
| Interest coverage ratio | 146.3x |
| Cash | CN¥3.13b |
| Equity | CN¥5.95b |
| Total liabilities | CN¥8.32b |
| Total assets | CN¥14.27b |
Recent financial health updates
Recent updates
Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25
Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings
Jun 25We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease
May 25Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
Apr 17Financial Position Analysis
Short Term Liabilities: 600664's short term assets (CN¥10.7B) exceed its short term liabilities (CN¥7.9B).
Long Term Liabilities: 600664's short term assets (CN¥10.7B) exceed its long term liabilities (CN¥432.9M).
Debt to Equity History and Analysis
Debt Level: 600664 has more cash than its total debt.
Reducing Debt: 600664's debt to equity ratio has increased from 8.1% to 30.2% over the past 5 years.
Debt Coverage: 600664's debt is not well covered by operating cash flow (18%).
Interest Coverage: 600664's interest payments on its debt are well covered by EBIT (146.3x coverage).